Cargando…
Targeted treatment of solid tumors in pediatric precision oncology
The treatment of childhood solid cancer has markedly evolved in recent years following a refined molecular characterization and the introduction of novel targeted drugs. On one hand, larger sequencing studies have revealed a spectrum of mutations in pediatric tumors different from adults. On the oth...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196192/ https://www.ncbi.nlm.nih.gov/pubmed/37213274 http://dx.doi.org/10.3389/fonc.2023.1176790 |
_version_ | 1785044292698374144 |
---|---|
author | Bertacca, Ilaria Pegoraro, Francesco Tondo, Annalisa Favre, Claudio |
author_facet | Bertacca, Ilaria Pegoraro, Francesco Tondo, Annalisa Favre, Claudio |
author_sort | Bertacca, Ilaria |
collection | PubMed |
description | The treatment of childhood solid cancer has markedly evolved in recent years following a refined molecular characterization and the introduction of novel targeted drugs. On one hand, larger sequencing studies have revealed a spectrum of mutations in pediatric tumors different from adults. On the other hand, specific mutations or immune dysregulated pathways have been targeted in preclinical and clinical studies, with heterogeneous results. Of note, the development of national platforms for tumor molecular profiling and, in less measure, for targeted treatment, has been essential in the process. However, many of the available molecules have been tested only in relapsed or refractory patients, and have proven poorly effective, at least in monotherapy. Our future approaches should certainly aim at improving the access to molecular characterization, to obtain a deeper picture of the distinctive phenotype of childhood cancer. In parallel, the implementation of access to novel drugs should not only be limited to basket or umbrella studies but also to larger, multi-drug international studies. In this paper we reviewed the molecular features and the main available therapeutic options in pediatric solid cancer, focusing on available targeted drugs and ongoing investigations, aiming at providing a useful tool to navigate the heterogeneity of this promising but complex field. |
format | Online Article Text |
id | pubmed-10196192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101961922023-05-20 Targeted treatment of solid tumors in pediatric precision oncology Bertacca, Ilaria Pegoraro, Francesco Tondo, Annalisa Favre, Claudio Front Oncol Oncology The treatment of childhood solid cancer has markedly evolved in recent years following a refined molecular characterization and the introduction of novel targeted drugs. On one hand, larger sequencing studies have revealed a spectrum of mutations in pediatric tumors different from adults. On the other hand, specific mutations or immune dysregulated pathways have been targeted in preclinical and clinical studies, with heterogeneous results. Of note, the development of national platforms for tumor molecular profiling and, in less measure, for targeted treatment, has been essential in the process. However, many of the available molecules have been tested only in relapsed or refractory patients, and have proven poorly effective, at least in monotherapy. Our future approaches should certainly aim at improving the access to molecular characterization, to obtain a deeper picture of the distinctive phenotype of childhood cancer. In parallel, the implementation of access to novel drugs should not only be limited to basket or umbrella studies but also to larger, multi-drug international studies. In this paper we reviewed the molecular features and the main available therapeutic options in pediatric solid cancer, focusing on available targeted drugs and ongoing investigations, aiming at providing a useful tool to navigate the heterogeneity of this promising but complex field. Frontiers Media S.A. 2023-05-05 /pmc/articles/PMC10196192/ /pubmed/37213274 http://dx.doi.org/10.3389/fonc.2023.1176790 Text en Copyright © 2023 Bertacca, Pegoraro, Tondo and Favre https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Bertacca, Ilaria Pegoraro, Francesco Tondo, Annalisa Favre, Claudio Targeted treatment of solid tumors in pediatric precision oncology |
title | Targeted treatment of solid tumors in pediatric precision oncology |
title_full | Targeted treatment of solid tumors in pediatric precision oncology |
title_fullStr | Targeted treatment of solid tumors in pediatric precision oncology |
title_full_unstemmed | Targeted treatment of solid tumors in pediatric precision oncology |
title_short | Targeted treatment of solid tumors in pediatric precision oncology |
title_sort | targeted treatment of solid tumors in pediatric precision oncology |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196192/ https://www.ncbi.nlm.nih.gov/pubmed/37213274 http://dx.doi.org/10.3389/fonc.2023.1176790 |
work_keys_str_mv | AT bertaccailaria targetedtreatmentofsolidtumorsinpediatricprecisiononcology AT pegorarofrancesco targetedtreatmentofsolidtumorsinpediatricprecisiononcology AT tondoannalisa targetedtreatmentofsolidtumorsinpediatricprecisiononcology AT favreclaudio targetedtreatmentofsolidtumorsinpediatricprecisiononcology |